GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Black Bird Biotech Inc (OTCPK:BBBT) » Definitions » Equity-to-Asset

Black Bird Biotech (Black Bird Biotech) Equity-to-Asset : -9.32 (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Black Bird Biotech Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Black Bird Biotech's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-0.92 Mil. Black Bird Biotech's Total Assets for the quarter that ended in Sep. 2023 was $0.10 Mil. Therefore, Black Bird Biotech's Equity to Asset Ratio for the quarter that ended in Sep. 2023 was -9.32.

The historical rank and industry rank for Black Bird Biotech's Equity-to-Asset or its related term are showing as below:

BBBT' s Equity-to-Asset Range Over the Past 10 Years
Min: -1141   Med: -35.84   Max: 0.87
Current: -9.32

During the past 13 years, the highest Equity to Asset Ratio of Black Bird Biotech was 0.87. The lowest was -1141.00. And the median was -35.84.

BBBT's Equity-to-Asset is ranked worse than
98.44% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs BBBT: -9.32

Black Bird Biotech Equity-to-Asset Historical Data

The historical data trend for Black Bird Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Black Bird Biotech Equity-to-Asset Chart

Black Bird Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -203.80 -1,141.00 0.22 0.87 -2.97

Black Bird Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.89 -2.97 -3.80 -8.22 -9.32

Competitive Comparison of Black Bird Biotech's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Black Bird Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Black Bird Biotech's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Black Bird Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Black Bird Biotech's Equity-to-Asset falls into.



Black Bird Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Black Bird Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-0.65/0.219
=-2.97

Black Bird Biotech's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=-0.923/0.099
=-9.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Black Bird Biotech  (OTCPK:BBBT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Black Bird Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Black Bird Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Black Bird Biotech (Black Bird Biotech) Business Description

Traded in Other Exchanges
N/A
Address
11961 Hilltop Road, Suite 22, Argyle, TX, USA, 76226
Black Bird Biotech Inc is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. In addition, it is the distributor in the U. S. and Canada for MiteXstream, an EPA-registered plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Its products include MiteXstream Biopesticide, Grizzly Creek Naturals, and Black Bird American Hemp.
Executives
Jeffrey A Collins director, 10 percent owner, officer: President 302 WASHINGTON ST., #513, SAN DIEGO CA 92103
Robert Edward Shea director, 10 percent owner, officer: President, CEO, CFO, CAO 40 WARREN STREET, 3RD FLOOR, CHARLESTOWN MA 02129
John James Sutherland director, 10 percent owner, officer: President, CEO, CFO & CAO C/O SUITE 810 - 675 WEST HASTINGS STREET, VANCOUVER A1 V6B 1N2

Black Bird Biotech (Black Bird Biotech) Headlines

From GuruFocus